Latest news articles

Added 23 days ago Drug news

EMA recommends adding efficacy data to Apealea label

Oasmia Pharmaceutical announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending approval...

Added 28 days ago Drug news

Phase III JAVELIN Ovarian PARP 100 study is discontinued

Merck KGaA and Pfizer Inc. have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating...

Added 1 month ago Drug news

Phase III FORWARD study of mirvetuximab soravtansine did not meet its primary endpoint to treat (FR alfa)-positive, platinum-resistant ovarian cancer

ImmunoGen, Inc., announced that its Phase III FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to...

Search all news articles for Cancer of ovary
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Guidelines

Management of epithelial ovarian cancer

This guideline provides recommendations based on current evidence for best practice in screening and the role of prophylactic salpingo-oophorectomy; diagnosis; surgical management; chemotherapy; follow up; management...

Added 5 years ago

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on non-epithelial ovarian cancer covers diagnosis and pathology/molecular biology, staging and risk assessment, treatment plan...

Added 5 years ago

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on non-epithelial ovarian cancer covers diagnosis and pathology/molecular biology, staging and risk assessment, treatment plan for early and advanced stages...

Added 6 years ago

Search all guidelines for Cancer of ovary
 

Journal articles

Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.

Recently, Poly-ADP-Ribose Polymerase (PARP) inhibitors are one of the most intensively studied group of antiblastic agents for the management of recurrent ovarian cancer.

Added 10 months ago

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins (PARP-1, PARP-2 and PARP-3) that play an important role in repairing DNA damage and maintaining genomic stability.

Added 10 months ago

Rucaparib: a new treatment option for ovarian cancer.

Areas covered: In this review, the authors discuss the efficacy and toxicity of rucaparib either as a single agent or as a maintenance treatment for ovarian cancer.

Added 10 months ago

Search all journal articles for Cancer of ovary
 

Clinical trials

PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...

Added 2 years ago

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3)

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib...

Added 6 years ago

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Added 10 months ago

Search all clinical trials for Cancer of ovary
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Ovarian cancer: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Cancer of ovary